Straumann Holding AG Research and Development Expenses 2012-2025 | SAUHY
Straumann Holding AG annual/quarterly research and development expenses history and growth rate from 2012 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Straumann Holding AG research and development expenses for the quarter ending December 31, 2025 were $0M, a 0% increase year-over-year.
- Straumann Holding AG research and development expenses for the twelve months ending December 31, 2025 were $0M, a 0% increase year-over-year.
- Straumann Holding AG annual research and development expenses for 2025 were $0B, a 0% decline from 2024.
- Straumann Holding AG annual research and development expenses for 2024 were $0B, a 0% decline from 2023.
- Straumann Holding AG annual research and development expenses for 2023 were $0B, a 0% decline from 2022.
|
Straumann Holding AG Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | |
| 2024 | |
| 2023 | |
| 2022 | |
| 2021 | |
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $44 |
|
Straumann Holding AG Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025-12-31 | |
| 2025-06-30 | |
| 2024-12-31 | |
| 2024-06-30 | |
| 2023-12-31 | |
| 2022-12-31 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2020-06-30 | |
| 2019-12-31 | |
| 2018-12-31 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| 2016-06-30 | |
| 2015-12-31 | |
| 2014-12-31 | |
| 2013-12-31 | |
| 2013-06-30 | |
| 2012-12-31 | |
| 2012-06-30 | |
| 2011-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $16.902B | $3.144B |
| The Straumann Group is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately on thousand seven hundred ninety people worldwide and its products and services are available in more than sixty countries through its broad network of distribution subsidiaries and partners. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| Becton Dickinson (BDX) | United States | $43.913B | 11.10 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |